LSL PHARMA GROUP INC announced the appointment of Mr. Luc Mainville as Chief Financial Officer effective December 4, 2023. Mr. Mainville brings extensive experience in the capital markets and life sciences industry. He is recognized for his financial and operational leadership having been associated with several fast-growing companies.

In an executive management career spanning more than 30 years, he has been involved in numerous public and private financings totaling in excess of $500 million and more than 50 corporate transactions, including initial public offerings, licensing, as well as mergers and acquisitions. Over the last five years, Mr. Mainville acted as Senior Vice President and Chief Financial Officer of Valeo Pharma, a fast-growing Canadian pharmaceutical company. During his tenure at Valeo, he raised in excess of $100 million helping Valeo increase its revenues 15 fold.

Prior to that, he held senior management positions with various life sciences companies, including Acerus Pharma, Cardiome Pharma, Neopharm Labs and LAB Research. Prior to his career in the life sciences sector, he was partner with KPMG, LLP. He holds an MBA from McGill University.

Luc Mainville has been Director of LSL Pharma since February 2023, and will relinquish his board position when joining the Company.